Lyell Immunopharma completes LYL273 manufacturing transfer; trial data pushed to 2027
Lyell Immunopharma said it completed the technology transfer of LYL273, its GCC-targeted CAR T-cell candidate, to its LyFE facility in Bothell, Washington, after FDA review of an improved manufacturing process. The company also said additional clinical data from the Phase 1/2 trial in metastatic colorectal cancer and an End-of-Phase 1 meeting with the FDA are now expected in 2027, which pushes out the timeline for those milestones.
Key points
- Technology transfer to the LyFE facility in Bothell, Washington, completed following FDA review of an improved manufacturing process and updated analytical methods
- Dosing of additional patients with the new process continues, with the goal of determining the recommended Phase 2 dose and optimized safety management plan
- Additional clinical data and the End-of-Phase 1 meeting with the FDA are now expected in 2027
- In June 2026, the company reported that gastrointestinal prophylaxis reduced Grade ≥ 2 diarrhea/colitis from 55% without prophylaxis to 10% with prophylaxis
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.